Core Viewpoint - South Africa has launched its first locally produced foot-and-mouth disease vaccine in 20 years to combat a severe outbreak affecting the country's beef and dairy industries [1] Group 1: Vaccine Production - The South African government announced the production of 12,900 doses of the vaccine, which will be distributed across multiple provinces to strengthen the frontline defense against the outbreak [1] - Production of the vaccine was halted in 2005 due to aging equipment and production technology, but modernization efforts have enabled the successful production of the vaccine [1] Group 2: Current Outbreak and Impact - The current outbreak of foot-and-mouth disease began in April 2025 in KwaZulu-Natal province and has rapidly spread to several key agricultural areas [1] - The outbreak has severely impacted the local beef export and dairy industries, prompting the government to implement a national control strategy and vaccination program [1] Group 3: Disease Characteristics - Foot-and-mouth disease is a viral infection that primarily affects cloven-hoofed animals such as cattle, sheep, and pigs, with symptoms including fever and the formation of blisters in the mouth and on the hooves [1] - While the disease is less likely to infect humans, there is a risk of transmission through close contact with infected animals [1]

Core Viewpoint - The report from Huachuang Securities indicates that while the industry is facing challenges due to increased competition, there is a stabilization and recovery in the prices of veterinary raw materials and vaccines, driven by innovation among successful companies [1] Vaccine Batch Release - In 2025, most vaccine varieties are expected to see year-on-year growth in batch releases, with new vaccines performing particularly well [1] - Specific growth rates for pig vaccines include: foot-and-mouth disease vaccine +6.4%, porcine circovirus vaccine +13.0%, pseudorabies vaccine +5.1%, swine fever vaccine +11.7%, and porcine enterovirus vaccine +21.3% [1] - For poultry vaccines, notable increases include avian influenza trivalent vaccine +22.8%, Newcastle disease vaccine +8.8%, and duck infectious serositis vaccine +17.3% [1] - The brucellosis vaccine for ruminants saw a significant increase of +61.6%, while the small ruminant plague vaccine decreased by -16.2% [1] - In the pet vaccine sector, domestic rabies vaccine and domestic cat trivalent vaccine increased by +22.1% and +32.3% respectively [1] Subspecies Analysis - In 2025, the economic product porcine circovirus vaccine and the mandatory immunization swine fever vaccine are expected to see faster growth due to increased farming profitability and pig output [2] - The rapid growth of the avian influenza trivalent vaccine and duck infectious serositis vaccine is attributed to heightened awareness of poultry diseases [2] - The brucellosis vaccine continues to maintain high growth rates due to the introduction of new products, while the small ruminant plague vaccine has seen a decline due to a high base from the previous year [2] Pet Vaccine Performance - The domestic cat trivalent vaccine, launched in early 2024, continues to show high growth in 2025 due to effective market promotion and consumer education [3] - Different types of vaccines for the same disease show varied performance, with the single foot-and-mouth disease vaccine decreasing by -0.7% and the multi-valent vaccine increasing by +8.9% [3] - The porcine foot-and-mouth disease OA bivalent vaccine saw a growth of +12.3%, while the porcine circovirus vaccine increased by +19.7% [3] Veterinary Raw Material Prices - In 2025, the Veterinary Product Index (VPI) is expected to rise by 7.2% year-on-year, with significant price increases in macrolide products [4] - Specific price increases include: tylosin +29.5%, tiamulin +11.4%, and tilmicosin +22.9% [4] - However, some products like florfenicol and amoxicillin have seen price declines of -5.9% and -21.0% respectively [4] - The market is anticipated to remain weak in the short term due to ongoing pressures in the farming sector and the traditional off-season for veterinary drugs [4]

Investment Rating - The report maintains a recommendation rating for the animal health industry, indicating an expectation of growth in the sector over the next 3-6 months, surpassing the benchmark index by more than 5% [4][80]. Core Insights - In 2025, the majority of vaccine varieties saw a year-on-year increase in batch approvals, with notable growth in new vaccine products [6][7]. - The Veterinary Product Index (VPI) for animal medicines increased by 7.2% year-on-year, although there was significant differentiation among product categories [51][56]. - The report emphasizes the importance of innovation in driving performance among companies in the sector, highlighting that successful firms exhibit strong product, marketing, and capital operation innovations [68][71]. Summary by Sections Vaccine Batch Approvals - In December 2025, most vaccine products showed year-on-year growth in batch approvals, particularly in swine vaccines, with notable increases in foot-and-mouth disease vaccine (+24.2%) and pseudorabies vaccine (+1.2%) [6][7]. - For the entire year of 2025, swine vaccines such as foot-and-mouth disease, pseudorabies, and swine fever vaccines saw increases of +6.4%, +5.1%, and +11.7% respectively, while some vaccines like blue ear and swine parvovirus vaccines experienced declines of -3.7% and -4.5% [7][8]. Animal Medicine Raw Materials - The VPI index for animal medicines rose by 7.2% year-on-year in 2025, with significant price increases in macrolide products such as tylosin (+29.5%) and tiamulin (+29.8%), while others like florfenicol and amoxicillin saw declines of -5.9% and -21.0% respectively [51][56]. - The report notes that the market for animal medicines is expected to remain weak in the short term due to ongoing pressures in the breeding sector and seasonal factors [56][68]. Investment Recommendations - The report suggests focusing on undervalued companies with improvement potential, particularly those demonstrating innovation in products and operations. Recommended companies include Zhongmu Co., Ltd., Reap Bio, and others [68][71].

Core Viewpoint - South Africa is launching a ten-year phased national plan to control and eradicate foot-and-mouth disease (FMD), focusing on mass vaccination and enhanced livestock movement control to regain recognition as an FMD-free country [1][2] Group 1: Plan Overview - The plan will prioritize high-risk provinces, aiming for 100% vaccination coverage in farms and dairy farms, 90% in commercial herds, and 80% in community cattle herds, with a booster vaccination within three months [1] - The vaccination strategy will combine imported vaccines with local production, involving international partners from Argentina, Botswana, and Turkey [1] Group 2: Expected Outcomes - If the plan is executed as intended, FMD cases in high-risk areas are expected to decrease by approximately 75% within one year, achieving "FMD control certification" in the medium term [2] - The South African livestock industry is facing severe export restrictions due to the current outbreak, with an estimated loss of 5.6 billion Rand (approximately 330 million USD) in export revenue [2] Group 3: Disease Impact - Foot-and-mouth disease is a highly contagious viral infection affecting cloven-hoofed animals, leading to symptoms such as fever and lesions, which can significantly reduce the productivity of affected animals and impact meat and dairy production [2]

Core Viewpoint - South Africa's Minister of Agriculture, Stinheisen, announced a national foot-and-mouth disease (FMD) control strategy and a vaccination plan, seeking to declare the FMD outbreak a disaster status [1] Group 1: FMD Control Strategy - The FMD control strategy will be implemented in phases, starting with stabilization and consolidation, followed by gradual progression to eventually cease vaccination, aiming for recognition as a "FMD-free zone" by the World Organisation for Animal Health [1] - Northern Cape is the only province in South Africa that has not reported FMD cases since the latest outbreak began in April 2025 [1] Group 2: Vaccination and Risk Areas - Approximately 2 million animals have been vaccinated since the outbreak began [1] - KwaZulu-Natal, Gauteng, Free State, and North West provinces have been identified as high-risk areas with severe outbreaks, where large-scale vaccination efforts will commence immediately [1] Group 3: Vaccine Production and Monitoring - South Africa plans to increase the import of FMD vaccines and enhance local vaccine production capacity [1] - The country will strengthen its laboratory network and improve livestock identification and traceability systems to enhance monitoring and control of livestock movement [1]

Core Logic - The company has strong R&D barriers and a rich pipeline of new products, with the non-epidemic vaccine having received clinical approval, which could become the largest growth engine in the next 3-5 years if progress is smooth [1] Industry Dynamics - The animal health sector is expected to maintain a volume increase but price decrease trend due to weak recovery in the breeding industry and profit compression, with overall gross margins declining amid intense competition and product homogenization [2] Product Development - The company is a leader in the foot-and-mouth disease vaccine market, transitioning its core product logic to the subunit non-epidemic vaccine, which has a broad market potential. The market size is expected to reach 1.75 billion yuan in the first year and 3.5 billion yuan in the second year post-launch. The subunit non-epidemic vaccine is set to enter clinical trials in July 2025, with potential revenue contributions starting from late 2027 to early 2028 [3] Marketing Strategy - The company focuses on "big products + big clients," providing comprehensive solutions and building a multi-layered marketing system. Online and overseas market expansions are showing initial success, with pet direct sales increasing over fourfold year-on-year in the first half of 2025. The company has registered sales of foot-and-mouth products in countries like Pakistan and Vietnam, with plans for deeper market penetration in Mongolia and Central Asia [4] Financial Forecast - The company expects overall revenue of 1.604 billion, 2.035 billion, and 2.521 billion yuan for 2025-2027, with year-on-year growth rates of 27.74%, 26.91%, and 23.85%. The net profit attributable to shareholders is projected to be 304 million, 398 million, and 491 million yuan, with growth rates of 178.44%, 31.04%, and 23.55%, corresponding to P/E ratios of 64, 49, and 39 times [5]

Group 1 - South Africa is experiencing the most severe foot-and-mouth disease outbreak in its history, with rapid virus transmission and strong infectivity, posing an unprecedented disaster for the livestock industry [1] - The outbreak began in April 2025 in KwaZulu-Natal province and has spread to other key agricultural areas, prompting the South African Department of Agriculture to procure vaccines for emergency vaccination of 930,000 animals [1] - The outbreak highlights the importance of global animal disease prevention and presents overseas market expansion opportunities for domestic animal health companies with technological advantages [1] Group 2 - The animal health industry has a tightly linked upstream and downstream, with upstream raw material drug companies providing essential support for vaccine production, while downstream demand from farming recovery and overseas epidemic prevention needs drive industry growth [2] - Companies like Reap Bio focus on veterinary biological products, including foot-and-mouth disease vaccines, covering multiple sectors such as pigs, poultry, and pets [3] - Bio Company is a leading domestic animal health enterprise with designated production qualifications for strong immunity foot-and-mouth disease vaccines, consistently ranking first in the industry for vaccine batch approvals [4]

Core Insights - The "14th Five-Year Plan" emphasizes enhancing the participation of private enterprises in major project construction and improving the mechanism for private investment, aiming to stimulate private investment vitality and increase its proportion in the market [1] Group 1: Economic Development Initiatives - Hohhot is focusing on six major industrial clusters, including synthetic biology, advanced materials, future networks, low-altitude economy, commercial aerospace, and life health, to drive high-quality development of the private economy [2] - The city is implementing technological upgrades in manufacturing and promoting green transformation in key industries such as new materials and equipment manufacturing [2] Group 2: Traditional and Emerging Industries - Hohhot's traditional dairy industry is seeing significant upgrades with projects like Yili's milk powder and cheese expansions, setting benchmarks for transformation through technological innovation [3] - The new materials industry has established a complete silicon-based material industry chain, including a domestic first 10,000-ton high-purity electronic-grade polysilicon production line [3] - The renewable energy sector has achieved a total installed capacity of 21.38 million kilowatts, with new energy installations doubling to 7.095 million kilowatts since the beginning of the "14th Five-Year Plan" [3] Group 3: Business Environment Optimization - Hohhot has been optimizing its business environment by enhancing government services through digital empowerment, including the launch of an intelligent Q&A system for administrative services [4] - The city has implemented a "one-click search" for enterprise policies, consolidating 38 "immediate enjoyment" policies and 90 regular support policies for businesses [4] Group 4: Market Access and Tax Services - The time to establish a business has been reduced to 0.5 working days, with significant reductions in steps and materials required [5] - Innovations in tax services include a successful pilot for reverse invoicing in the agricultural product acquisition sector, which is expected to reduce tax management costs by about 25% [5] - Trade facilitation has improved with instant approval and printing of certificates of origin, enhancing the efficiency of the China-Europe freight train operations [5]

Core Viewpoint - The company, Pulaike, plans to acquire a 4.04% stake in Zhongpu Biological from CITIC Agriculture, which will make Pulaike the controlling shareholder of Zhongpu Biological, a company currently facing continuous losses in the production of foot-and-mouth disease vaccines [1][9]. Company Overview - Zhongpu Biological, formerly known as Baoshan Biological Pharmaceutical Factory, specializes in the research, production, and technical services of foot-and-mouth disease vaccines. It has been in a loss-making state due to declining industry conditions and overcapacity [1][10]. - Pulaike currently holds a 46.97% stake in Zhongpu Biological, while CITIC Agriculture holds 4.04%. After the acquisition, Pulaike's stake will increase to 51.01%, surpassing the current largest shareholder, Zhongmu Co., Ltd. [1][10]. Financial Performance - Zhongpu Biological is projected to generate revenue of 37.01 million yuan in 2024, with a loss of 26.21 million yuan. In the first half of 2025, it is expected to achieve revenue of 18.85 million yuan, with a loss of 18.24 million yuan [2][10]. - Pulaike's revenue for 2024 is expected to decline by 16.77% to 1.043 billion yuan, with a net profit drop of 46.82% to 92.81 million yuan. The gross margin has decreased by 4.32 percentage points, and the net margin has fallen by 13.32 percentage points to 8.9% [4][13]. Industry Challenges - The animal health industry is facing challenges due to a decline in market conditions and overcapacity, with the number of manufacturers producing foot-and-mouth disease vaccines increasing from 7 to 10, leading to an estimated total capacity exceeding 13 billion milliliters per year [2][11]. - The utilization rate of vaccine manufacturers is low, with some companies reporting as low as 20.83% utilization [2][11]. Operational Issues - Pulaike's core business of pig vaccines has been under pressure, with revenue from this segment declining by 22.6% to 336 million yuan in 2024, despite having a gross margin of 83.89% [4][13]. - The company has invested heavily in new production facilities, resulting in a significant increase in depreciation expenses, which rose by 20.65% in 2024 [5][14]. Recent Developments - In the first three quarters of the year, Pulaike's revenue grew by 8.04% to 823 million yuan, and net profit increased by 47.86% to 157 million yuan. However, the growth in net profit is attributed to cost-cutting measures rather than revenue growth [6][15]. - Despite some recovery in new business segments, the overall revenue has started to decline, with a 5.39% drop in the third quarter [7][16]. Accounts Receivable Concerns - As of the end of the third quarter, Pulaike's accounts receivable reached 335 million yuan, accounting for 41% of its revenue, indicating potential cash flow issues [7][16].

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., plans to acquire a 4.04% equity stake in Zhongpu Biological Pharmaceutical Co., Ltd. from CITIC Agriculture Technology Co., Ltd. This acquisition aims to gain control over Zhongpu Biological and improve its operational efficiency and sustainable development capabilities [2][4][5]. Transaction Overview - The transaction does not constitute a related party transaction or a major asset restructuring. It has been approved by the company's board of directors and does not require shareholder approval [3][4]. - The stake being acquired corresponds to an assessed value of 17.5143 million yuan, with the company having a priority purchase right upon the agreement of other shareholders [4][6]. Counterparty Information - CITIC Agriculture is a non-listed joint-stock company with a registered capital of approximately 11.14 billion yuan, established on December 15, 2014. It operates independently from the company in terms of assets and liabilities [5][6]. Target Asset Information - The target asset for this transaction is the 4.04% equity stake in Zhongpu Biological, which is free from any encumbrances or legal disputes [6][7]. - Zhongpu Biological was established in June 2018 with a registered capital of 432.72 million yuan, primarily engaged in the production and sale of veterinary vaccines [7]. Valuation and Pricing - The valuation of the equity stake was conducted by Beijing Zhongqi Hua Asset Appraisal Co., Ltd., using both asset-based and market approaches, with the market approach being favored for its objectivity and relevance to current market conditions [8][9]. Impact on the Company - If the transaction is completed, the company will gain control over Zhongpu Biological, which aligns with its strategic development goals and benefits shareholder interests. The transaction is not expected to lead to management changes or non-operational fund occupation by major shareholders [9].